Brand Engagement Network (BNAI) said Monday that it has signed an agreement with an advertising agency to develop a customized artificial intelligence engagement tool for a client's prescription drug.

The company said it expects to recognize $250,000 in revenue in Q4 for services rendered under two statements of work as well as monthly recurring license fees in Q1 2026.

The company said this contract, along with its Latin American licensing partnership and the launch of Skye Salud in Mexico, is expected to contribute positively to its Q4 financial results.

The identities of the ad agency and its client will remain confidential until the release of the AI tool, the company said.

Brand Engagement Network shares were up more than 19% in recent Monday premarket activity.